Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ANPEP | P15144 | 1/20 | 0.54 |
| ▸ | ENPEP | Q07075 | 1/20 | 0.54 |
| ▸ | S1PR2 | O95136 | 5/20 | 0.38 |
| ▸ | S1PR1 | P21453 | 5/20 | 0.38 |
| ▸ | S1PR3 | Q99500 | 5/20 | 0.38 |
| ▸ | S1PR4 | O95977 | 4/20 | 0.38 |
| ▸ | PLA2G1B | P04054 | 1/20 | 0.38 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.38 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
| ▸ | FDPS | P14324 | 1/20 | 0.33 |
| ▸ | DNM1 | Q05193 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20212341 | 1.00 | ANPEP (0.54) | ANPEPENPEPS1PR2S1PR1S1PR3 | |
| SCHEMBL272998 | 0.82 | OPRM1 (0.50) | S1PR2S1PR1S1PR3S1PR4PLA2G1B | |
| SCHEMBL25686241 | 0.81 | ALDH1A1 (0.44) | ANPEPENPEPS1PR2S1PR1S1PR3 | |
| Fluoride SCHEMBL1995827 | 0.79 | OPRM1 (0.48) | S1PR2S1PR1S1PR3S1PR4PLA2G1B | |
| Bromide SCHEMBL1993996 | 0.79 | OPRM1 (0.48) | S1PR2S1PR1S1PR3S1PR4PLA2G1B | |
| Hydrochloric Acid SCHEMBL1997517 | 0.79 | OPRM1 (0.48) | S1PR2S1PR1S1PR3S1PR4PLA2G1B | |
| SCHEMBL22519748 | 0.78 | FDPS (0.39) | ANPEPENPEPOPRM1FDPSDNM1 | |
| SCHEMBL18822314 | 0.77 | — | — | |
| SCHEMBL12257894 | 0.77 | — | — | |
| SCHEMBL18822350 | 0.77 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250073236-A1 | PYRIMIDINE COMPOUNDS CONTAINING ACIDIC GROUPS | APROS THERAPEUTICS INC (US) | 2025-03-06 | — | — | US | disclosed |
| CN-110177780-B | Pyrimidine compounds containing acidic groups | 阿普罗斯治疗公司 | 2022-11-01 | — | — | CN | disclosed |
| EP-3548478-B1 | PYRIMIDINE COMPOUNDS CONTAINING ACIDIC GROUPS | APROS THERAPEUTICS INC (US) | 2021-11-17 | — | — | EP | disclosed |
| EP-3548478-B1 | PYRIMIDINE COMPOUNDS CONTAINING ACIDIC GROUPS | APROS THERAPEUTICS INC (US) | 2021-11-17 | — | — | EP | disclosed |
| US-11173157-B2 | Substituted pyrimidines containing acidic groups as TLR7 modulators | Apros Therapeutics, Inc. (US) | 2021-11-16 | — | — | US | disclosed |
| US-11173157-B2 | Substituted pyrimidines containing acidic groups as TLR7 modulators | Apros Therapeutics, Inc. (US) | 2021-11-16 | — | — | US | disclosed |
| US-20210228713-A1 | TLR7 PEPTIDE CONJUGATES | Apros Therapeutics, Inc. | 2021-07-29 | — | — | US | disclosed |
| US-20210228713-A1 | TLR7 PEPTIDE CONJUGATES | Apros Therapeutics, Inc. | 2021-07-29 | — | — | US | disclosed |
| EP-3801628-A1 | TLR7 PEPTIDE CONJUGATES | Apros Therapeutics, Inc. (US) | 2021-04-14 | — | — | EP | disclosed |
| CN-112513031-A | Acid group containing pyrimidine compounds useful for the treatment of diseases associated with the modulation of TLR7 | 阿普罗斯治疗公司 | 2021-03-16 | — | — | CN | disclosed |
| CN-110177780-A | Pyrimidine compound containing acidic groups | 阿普罗斯治疗公司 | 2019-08-27 | — | — | CN | disclosed |
| US-10287253-B2 | Substituted pyrimidines containing acidic groups as TLR7 modulators | Apros Therapeutics, Inc. (US) | 2019-05-14 | — | — | US | disclosed |
| US-10287253-B2 | Substituted pyrimidines containing acidic groups as TLR7 modulators | Apros Therapeutics, Inc. (US) | 2019-05-14 | — | — | US | disclosed |
| WO-2018106606-A1 | PYRIMIDINE COMPOUNDS CONTAINING ACIDIC GROUPS | Apros Therapeutics, Inc. (US) | 2018-06-14 | — | — | WO | disclosed |
| WO-2018106606-A1 | PYRIMIDINE COMPOUNDS CONTAINING ACIDIC GROUPS | Apros Therapeutics, Inc. (US) | 2018-06-14 | — | — | WO | disclosed |
| US-20180155298-A1 | PYRIMIDINE COMPOUNDS CONTAINING ACIDIC GROUPS | Apros Therapeutics, Inc. | 2018-06-07 | — | — | US | disclosed |
| US-20180155298-A1 | PYRIMIDINE COMPOUNDS CONTAINING ACIDIC GROUPS | Apros Therapeutics, Inc. | 2018-06-07 | — | — | US | disclosed |
| US-20180155298-A1 | PYRIMIDINE COMPOUNDS CONTAINING ACIDIC GROUPS | Apros Therapeutics, Inc. | 2018-06-07 | — | — | US | disclosed |
| US-20170342035-A1 | 2-AMINOPYRIMIDINE DERIVATIVES FOR THE TREATMENT OF VIRAL INFECTIONS | JANSSEN SCIENCES IRELAND UC (IE) | 2017-11-30 | — | — | US | disclosed |
| US-9598378-B2 | 2-aminopyrimidine derivatives for the treatment of viral infections | JANSSEN SCIENCES IRELAND UC (IE) | 2017-03-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180155298-A1 | PYRIMIDINE COMPOUNDS CONTAINING ACIDIC GROUPS | MAVS, TLR7, STING1 | ANPEP 2443/4885ENPEP 975/4885S1PR2 1422/4885 |
| US-20210228713-A1 | TLR7 PEPTIDE CONJUGATES | TLR7, TLR9, TLR8 | ANPEP 297/4885ENPEP 365/4885S1PR2 3718/4885 |
| US-20250073236-A1 | PYRIMIDINE COMPOUNDS CONTAINING ACIDIC GROUPS | MAVS, TLR7, STING1 | ANPEP 2443/4885ENPEP 975/4885S1PR2 1422/4885 |
| US-20170342035-A1 | 2-AMINOPYRIMIDINE DERIVATIVES FOR THE TREATMENT OF VIRAL INFECTIONS | DPYD, EIF2AK2, TYMP | ANPEP 243/4885ENPEP 365/4885S1PR2 2515/4885 |
| US-10287253-B2 | Substituted pyrimidines containing acidic groups as TLR7 modulators | TLR7, TLR9, MAVS | ANPEP 3094/4885ENPEP 1437/4885S1PR2 992/4885 |
| US-11173157-B2 | Substituted pyrimidines containing acidic groups as TLR7 modulators | TLR7, TLR9, MAVS | ANPEP 3094/4885ENPEP 1437/4885S1PR2 992/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.